Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SoFT trial of sevelamer effects on FGF23 in chronic kidney disease
2013-002373-22Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sevelamer carbonate in chronic kidney disease (CKD) and cardiac morbidity, sponsored by Amsterdam University Medical Center. Primary endpoints: Absolute change in C-terminal FGF-23 and Percentage change in C-terminal FGF-23. Started Oct 2013; status: active.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2013-002373-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002373-22.